Canada - Tiếng Anh - Health Canada

celltrion healthcare co ltd - bevacizumab - solution - 400mg - bevacizumab 400mg

Canada - Tiếng Anh - Health Canada

hoffmann-la roche limited - bevacizumab - solution - 25mg - bevacizumab 25mg - antineoplastic agents

Canada - Tiếng Anh - Health Canada

pfizer canada ulc - bevacizumab - solution - 100mg - bevacizumab 100mg - antineoplastic agents

Canada - Tiếng Anh - Health Canada

pfizer canada ulc - bevacizumab - solution - 400mg - bevacizumab 400mg - antineoplastic agents

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bevacizumab, quantity: 400 mg - injection, concentrated - excipient ingredients: sucrose; sodium hydroxide; succinic acid; polysorbate 80; disodium edetate; water for injections - metastatic colorectal cancer,zirabev (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.,locally recurrent or metastatic breast cancer,zirabev (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.,advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc),zirabev (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non- small cell lung cancer.,advanced and/or metastatic renal cell cancer,zirabev (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.,grade iv glioma,zirabev (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy.,epithelial ovarian, fallopian tube or primary peritoneal cancer,zirabev (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.,recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer,zirabev (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors.,zirabev (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab.,cervical cancer,zirabev (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. zirabev (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - bevacizumab, quantity: 100 mg - injection, concentrated - excipient ingredients: succinic acid; water for injections; sodium hydroxide; sucrose; polysorbate 80; disodium edetate - metastatic colorectal cancer,zirabev (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer.,locally recurrent or metastatic breast cancer,zirabev (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.,advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc),zirabev (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous, non- small cell lung cancer.,advanced and/or metastatic renal cell cancer,zirabev (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer.,grade iv glioma,zirabev (bevacizumab) as a single agent, is indicated for the treatment of patients with grade iv glioma after relapse or disease progression after standard therapy, including chemotherapy.,epithelial ovarian, fallopian tube or primary peritoneal cancer,zirabev (bevacizumab) in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with advanced (figo stages iiib, iiic and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer.,recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer,zirabev (bevacizumab), in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, is indicated for the treatment of patients with first recurrence of platinum-sensitive, epithelial ovarian, fallopian tube, or primary peritoneal cancer who have not received prior bevacizumab or other vegf-targeted angiogenesis inhibitors.,zirabev (bevacizumab) in combination with paclitaxel, topotecan or pegylated liposomal doxorubicin is indicated for the treatment of patients with recurrent, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than two prior chemotherapy regimens, and have not received any prior anti-angiogenic therapy including bevacizumab.,cervical cancer,zirabev (bevacizumab) in combination with paclitaxel and cisplatin is indicated for the treatment of persistent, recurrent or metastatic carcinoma of the cervix. zirabev (bevacizumab) in combination with paclitaxel and topotecan is an acceptable alternative where cisplatin is not tolerated or not indicated.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - bevacizumab 25 mg/ml;  ;   - concentrate for infusion - 25 mg/ml - active: bevacizumab 25 mg/ml     excipient: dibasic sodium phosphate monobasic sodium phosphate monohydrate polysorbate 20 trehalose water for injection - metastatic colorectal cancer. avastin in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

pfizer europe ma eeig - bevacizumab - colorectal neoplasms; breast neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastic agents - zirabev in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.zirabev in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. for further information as to human epidermal growth factor receptor 2 (her2) status.zirabev, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.zirabev in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.zirabev, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.

Kenya - Tiếng Anh - Pharmacy and Poisons Board

f. hoffman-la roche ltd p.o. box 44212 - 00100 nairobi - bevacizumab - injection - bevacizumab 100mg - other antineoplastic agents: monoclonal antibodies

Kenya - Tiếng Anh - Pharmacy and Poisons Board

f. hoffman-la roche ltd p.o. box 44212 - 00100 nairobi - bevacizumab - injection - bevacizumab 400mg - other antineoplastic agents: monoclonal antibodies